Peptide Research

Ipamorelin Side Effects: What Selectivity Actually Removes

Ipamorelin’s reputation rests on what it does not do. The selectivity claim is well founded and narrower than it is usually presented.

Peptide Library Editorial · October 4, 2026 · 3 min read

Ipamorelin Side Effects: What Selectivity Actually Removes — Peptide Library research guide

Ipamorelin’s reputation is built on what it avoids rather than what it does. The 1998 paper that introduced it described the first selective growth hormone secretagogue — prompting GH release without the cortisol and prolactin increases characteristic of earlier GHRPs.

That claim is well founded and narrower than it is usually presented.

An absence of reported side effects is not a safety record. Ipamorelin has no approved indication and no human safety trial. Nothing has systematically collected adverse events, so "few reported side effects" reflects the absence of anyone looking rather than evidence of safety.

What selectivity removes

Effect

Older GHRPs

Ipamorelin

Cortisol increase

Yes

Minimal

Prolactin increase

Yes

Minimal

Marked appetite stimulation

Yes, especially GHRP-6

Minimal

GH release

Yes

Yes — moderate

Compare with hexarelin, which produces the largest GH response in the family and raises cortisol and prolactin, and GHRP-2, which sits between them. Potency and unwanted activity rise together across the class.

What selectivity does not remove

This is the part usually skipped. Ipamorelin still raises growth hormone, so the effects that follow from raised growth hormone still apply:

  • Fluid retention. A recognised GH effect. Less likely from a brief pulse than sustained elevation, but not eliminated.

  • Joint aches. The same mechanism.

  • Tingling or numbness. Reported with GH-axis compounds generally.

  • Insulin sensitivity. Growth hormone opposes insulin. A pulse is a smaller intervention than sustained elevation, not a null one.

  • Head rush or flushing shortly after injection, commonly described.

  • Injection site reactions. As with any subcutaneous peptide.

Selectivity is about receptor cross-talk, not about GH itself. It means the compound does not drag cortisol and prolactin along. Everything downstream of raising growth hormone is still in play, because that is the intended effect.

The pulse argument

Ipamorelin has a half-life around two hours and produces a pulse rather than sustained elevation. That matters for the GH-related effects above, which track sustained exposure more than transient peaks.

It is the clearest structural difference from MK-677, which raises GH and IGF-1 for around a day per dose and is correspondingly better known for water retention.

What remains unknown

Ipamorelin has never been approved, so there is no adverse-event reporting or post-marketing surveillance. Long-term exposure, effects on the GH/IGF-1 axis over years, and interactions are uncharacterised.

The theoretical GH/IGF-1 considerations discussed in the sermorelin side effects guide apply to any compound raising this axis.

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

Frequently asked questions

Does ipamorelin raise cortisol?

Minimally — that is the specific selectivity claim its original research supports, and it distinguishes it from older GHRPs.

Does it cause water retention?

Less than sustained-elevation approaches, because it produces a pulse. Fluid retention is a GH effect, so it is reduced rather than absent.

Is it the safest GHRP?

It is the most selective, which is a real advantage. "Safest" implies comparative safety data that does not exist for any compound in this class.

Research and educational use only. Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.

Sources

  1. 1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue — European Journal of Endocrinology (1998) Source PubMed
  2. 2. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Frontiers in Endocrinology (2026) Source PubMed

Author

Peptide Library Editorial

Editorial content from Peptide Library. Research and educational use only. Not medical advice.

Research smarter with Peptide Library.

Compare peptides, review vendor data, and use research calculators in one place.

Explore the Library

Research and educational use only. Not medical advice. Peptide Library does not sell peptides.